189 related articles for article (PubMed ID: 37121942)
1. Integrative multi-omics and drug-response characterization of patient-derived prostate cancer primary cells.
Wang Z; Li Y; Zhao W; Jiang S; Huang Y; Hou J; Zhang X; Zhai Z; Yang C; Wang J; Zhu J; Pan J; Jiang W; Li Z; Ye M; Tan M; Jiang H; Dang Y
Signal Transduct Target Ther; 2023 May; 8(1):175. PubMed ID: 37121942
[TBL] [Abstract][Full Text] [Related]
2. The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection.
Bu H; Bormann S; Schäfer G; Horninger W; Massoner P; Neeb A; Lakshmanan VK; Maddalo D; Nestl A; Sültmann H; Cato AC; Klocker H
Prostate; 2011 May; 71(6):575-87. PubMed ID: 20945500
[TBL] [Abstract][Full Text] [Related]
3. Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer.
Neeb A; Hefele S; Bormann S; Parson W; Adams F; Wolf P; Miernik A; Schoenthaler M; Kroenig M; Wilhelm K; Schultze-Seemann W; Nestel S; Schaefer G; Bu H; Klocker H; Nazarenko I; Cato AC
Oncotarget; 2014 Sep; 5(18):8681-9. PubMed ID: 25237833
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis reveals a macrophage-related marker gene signature for prognostic prediction, immune landscape, genomic heterogeneity, and drug choices in prostate cancer.
Zhu W; Wu J; Huang J; Xiao D; Li F; Wu C; Li X; Zeng H; Zheng J; Lai W; Wen X
Front Immunol; 2023; 14():1122670. PubMed ID: 37122696
[TBL] [Abstract][Full Text] [Related]
5. ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer.
Zhang Y; Ali TZ; Zhou H; D'Souza DR; Lu Y; Jaffe J; Liu Z; Passaniti A; Hamburger AW
Cancer Res; 2010 Jan; 70(1):240-8. PubMed ID: 20048076
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of AGR2 induces cellular senescence in prostate cancer cells.
Hu Z; Gu Y; Han B; Zhang J; Li Z; Tian K; Young CY; Yuan H
Carcinogenesis; 2012 Jun; 33(6):1178-86. PubMed ID: 22467239
[TBL] [Abstract][Full Text] [Related]
7. Anterior gradient 2 and 3--two prototype androgen-responsive genes transcriptionally upregulated by androgens and by oestrogens in prostate cancer cells.
Bu H; Schweiger MR; Manke T; Wunderlich A; Timmermann B; Kerick M; Pasqualini L; Shehu E; Fuchsberger C; Cato AC; Klocker H
FEBS J; 2013 Mar; 280(5):1249-66. PubMed ID: 23294566
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer cell phenotypes based on AGR2 and CD10 expression.
Ho ME; Quek SI; True LD; Morrissey C; Corey E; Vessella RL; Dumpit R; Nelson PS; Maresh EL; Mah V; Alavi M; Kim SR; Bagryanova L; Horvath S; Chia D; Goodglick L; Liu AY
Mod Pathol; 2013 Jun; 26(6):849-59. PubMed ID: 23348903
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of anterior gradient gene AGR2 in prostate cancer.
Maresh EL; Mah V; Alavi M; Horvath S; Bagryanova L; Liebeskind ES; Knutzen LA; Zhou Y; Chia D; Liu AY; Goodglick L
BMC Cancer; 2010 Dec; 10():680. PubMed ID: 21144054
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients.
Zhang Y; Forootan SS; Liu D; Barraclough R; Foster CS; Rudland PS; Ke Y
Prostate Cancer Prostatic Dis; 2007; 10(3):293-300. PubMed ID: 17457305
[TBL] [Abstract][Full Text] [Related]
11. FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma.
Chianese U; Papulino C; Ali A; Ciardiello F; Cappabianca S; Altucci L; Carafa V; Benedetti R
J Transl Med; 2023 Jan; 21(1):32. PubMed ID: 36650542
[TBL] [Abstract][Full Text] [Related]
12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
13. Extended application of genomic selection to screen multiomics data for prognostic signatures of prostate cancer.
Li R; Wang S; Cui Y; Qu H; Chater JM; Zhang L; Wei J; Wang M; Xu Y; Yu L; Lu J; Feng Y; Zhou R; Huang Y; Ma R; Zhu J; Zhong W; Jia Z
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32898860
[TBL] [Abstract][Full Text] [Related]
14. Pro-metastatic activity of AGR2 interrupts angiogenesis target bevacizumab efficiency via direct interaction with VEGFA and activation of NF-κB pathway.
Jia M; Guo Y; Zhu D; Zhang N; Li L; Jiang J; Dong Y; Xu Q; Zhang X; Wang M; Yu H; Wang F; Tian K; Zhang J; Young CYF; Lou H; Yuan H
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1622-1633. PubMed ID: 29410027
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.
Parsons BM; Meier DR; Richmond CS; Gurda GT; Lofgren KA; Burkard ME; Deming DA; Kenny PA
Clin Breast Cancer; 2020 Aug; 20(4):e433-e438. PubMed ID: 32234363
[TBL] [Abstract][Full Text] [Related]
16. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer.
Heidegger I; Fotakis G; Offermann A; Goveia J; Daum S; Salcher S; Noureen A; Timmer-Bosscha H; Schäfer G; Walenkamp A; Perner S; Beatovic A; Moisse M; Plattner C; Krogsdam A; Haybaeck J; Sopper S; Thaler S; Keller MA; Klocker H; Trajanoski Z; Wolf D; Pircher A
Mol Cancer; 2022 Jun; 21(1):132. PubMed ID: 35717322
[TBL] [Abstract][Full Text] [Related]
18. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance.
Xu Y; Zhang F; Pan X; Wang G; Zhu L; Zhang J; Wen D; Lu S
Cancer Commun (Lond); 2018 May; 38(1):19. PubMed ID: 29764505
[TBL] [Abstract][Full Text] [Related]
19. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.
Kani K; Malihi PD; Jiang Y; Wang H; Wang Y; Ruderman DL; Agus DB; Mallick P; Gross ME
Prostate; 2013 Feb; 73(3):306-15. PubMed ID: 22911164
[TBL] [Abstract][Full Text] [Related]
20. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
